We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Dynorphin 1-13 on Heroin Addiction - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000244
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : May 27, 2015
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute

Brief Summary:
The purpose of this study is to evaluate the effects of IV dynorphin in humans during acute heroin abstinence, in order to determine that dynorphin suppresses acute opiate withdrawal, reduces opiate craving, and is safe at doses required to produce the above effects.

Condition or disease Intervention/treatment Phase
Opioid-Related Disorders Substance Withdrawal Syndrome Drug: Dynorphin 1 - 13 Phase 2

Detailed Description:
Randomized double blinded study of the effects of a single IV dose of dynorphin A 1-13 on heroin withdrawal in human opiate addicts

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 0 participants
Masking: Double
Primary Purpose: Treatment
Official Title: Effects of Dynorphin 1-13 on Heroin Addiction
Study Start Date : August 1994
Primary Completion Date : March 1997
Study Completion Date : March 1997

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heroin
U.S. FDA Resources




Primary Outcome Measures :
  1. Craving scale


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

opiate addict between the ages of 18-55

Exclusion Criteria:

Regular abuse of other drugs, unstable medical conditions


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000244


Locations
United States, Minnesota
U of Minnesota School of Medicine
Minneapolis, Minnesota, United States, 55415
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Paul Pentel, M.D. University of Minnesota - Clinical and Translational Science Institute

Publications:
Responsible Party: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier: NCT00000244     History of Changes
Other Study ID Numbers: NIDA-08067-1
R01DA008067 ( U.S. NIH Grant/Contract )
R01-08067-1
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: May 27, 2015
Last Verified: May 2015

Keywords provided by University of Minnesota - Clinical and Translational Science Institute:
addiction
opiate
heroin
dynorphin

Additional relevant MeSH terms:
Behavior, Addictive
Opioid-Related Disorders
Substance Withdrawal Syndrome
Heroin Dependence
Compulsive Behavior
Impulsive Behavior
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Heroin
Dynorphins
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action